Some considerations about cardiac toxicity of combination therapy for chronic hepatitis C
- PMID: 23967024
- PMCID: PMC3741906
- DOI: 10.5812/hepatmon.8962
Some considerations about cardiac toxicity of combination therapy for chronic hepatitis C
Keywords: Combined Modality Therapy; Hepatitis C; Interferon-Gamma; Ribavirin.
Comment on
- Is combination therapy for chronic hepatitis C toxic for cardiac function? Hepat Mon. 2012
Similar articles
-
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.J Hepatol. 1997 May;26(5):961-6. doi: 10.1016/s0168-8278(97)80103-1. J Hepatol. 1997. PMID: 9186825
-
Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.J Hepatol. 1995;23 Suppl 2:32-5; discussion 35-6. J Hepatol. 1995. PMID: 8720292 Review.
-
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.N Engl J Med. 1998 Nov 19;339(21):1485-92. doi: 10.1056/NEJM199811193392101. N Engl J Med. 1998. PMID: 9819446 Clinical Trial.
-
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.N Engl J Med. 1998 Nov 19;339(21):1493-9. doi: 10.1056/NEJM199811193392102. N Engl J Med. 1998. PMID: 9819447 Clinical Trial.
-
Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.Drugs. 2002;62(3):507-56. doi: 10.2165/00003495-200262030-00009. Drugs. 2002. PMID: 11827565 Review.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources